A Case of Bullous Pemphigoid after Administration of Erdafitinib
- Author:
Su Min LEE
1
;
Sook Jung YUN
;
Jee-Bum LEE
Author Information
1. Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea
- Publication Type:Case Report
- From:Korean Journal of Dermatology
2023;61(10):630-633
- CountryRepublic of Korea
- Language:English
-
Abstract:
Bullous pemphigoid (BP) is an acquired autoimmune disease characterized by subepidermal vesicles and bullae. It is now well-accepted that BP could be associated with therapeutic drugs. Immunotherapy can induce BP; however, few reports of tyrosine kinase inhibitor of fibroblast growth factor receptor-induced BP exist in the literature. A 67-year-old male presented with pruritic erythematous variable-sized patches with bullae on entire body. The patient was diagnosed with left renal cancer and treated by erdafitinib for clinical trial purposes. Bullae formation began at the start of the 11th month of erdafitinib administration. Histopathologic examination of the skin lesion showed subepidermal blister with eosinophils and other inflammatory cells in epidermis and dermis. Direct immunofluorescence showed a linear pattern of immunoglobulin G and C3 deposition along the basement membrane zone. The results of ELISA with recombinant purified BP180 and BP230 were positive. Consequently, the patient was diagnosed with erdafitinib-related BP.
